- Home
- DSM vs SERA Comparison
DSM vs SERA Comparison
Compare DSM & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- SERA
- Stock Information
- Founded
- DSM 1989
- SERA 2008
- Country
- DSM United States
- SERA United States
- Employees
- DSM N/A
- SERA N/A
- Industry
- DSM Investment Managers
- SERA Precision Instruments
- Sector
- DSM Finance
- SERA Health Care
- Exchange
- DSM Nasdaq
- SERA Nasdaq
- Market Cap
- DSM 301.5M
- SERA 258.3M
- IPO Year
- DSM N/A
- SERA 2021
- Fundamental
- Price
- DSM $6.02
- SERA $6.14
- Analyst Decision
- DSM
- SERA
- Analyst Count
- DSM 0
- SERA 0
- Target Price
- DSM N/A
- SERA N/A
- AVG Volume (30 Days)
- DSM 161.7K
- SERA 83.9K
- Earning Date
- DSM 01-01-0001
- SERA 11-06-2024
- Dividend Yield
- DSM 3.97%
- SERA N/A
- EPS Growth
- DSM N/A
- SERA N/A
- EPS
- DSM N/A
- SERA N/A
- Revenue
- DSM N/A
- SERA $94,000.00
- Revenue This Year
- DSM N/A
- SERA N/A
- Revenue Next Year
- DSM N/A
- SERA $2,018.04
- P/E Ratio
- DSM N/A
- SERA N/A
- Revenue Growth
- DSM N/A
- SERA N/A
- 52 Week Low
- DSM $4.69
- SERA $1.75
- 52 Week High
- DSM $6.05
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- DSM 44.97
- SERA 39.37
- Support Level
- DSM $6.00
- SERA $6.30
- Resistance Level
- DSM $6.09
- SERA $7.50
- Average True Range (ATR)
- DSM 0.07
- SERA 0.76
- MACD
- DSM 0.01
- SERA -0.16
- Stochastic Oscillator
- DSM 45.24
- SERA 7.04
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.